Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections

NCT00424190 | Completed Phase 3 Results

• 1 other identifier: P903-06
• Study Type: interventional
• Target: 698
• Locations: 11 countries
• Sites: 52

Brief Summary

The purpose of this study is to determine whether ceftaroline is effective and safe in the treatment of complicated skin infections in adults.

Conditions

Bacterial Infections

Keywords

Abscess; Antibacterial; Antibiotic; Antimicrobial; Bacterial infection, skin; Ceftaroline; Ceftaroline acetate; Cellulitis; Cephalosporin; Complicated skin and skin structure infection; cSSSI; Intravenous; Methicillin-resistant Staphylococcus Aureus (MRSA); PPI-0903; Prodrug; Skin disease, bacterial; Skin infection; Staphylococcal skin infection; Staphylococcus aureus; Streptococcal skin infection; Surgical site infection; TAK-599

Outcome Measures

Primary Outcomes (2)

• Clinical Cure Rate at Test of Cure (TOC) (MITT Population)

  Cure: Total resolution of all signs and symptoms of the baseline infection, or improvement of the infection such that no further antimicrobial therapy was necessary. Failure: Requirement of alternative antimicrobial therapy for primary infection of cSSSI due to inadequate response, recurrence, new infection at the same site; treatment-limiting adverse event (AE); requirement for surgery due to failure of study drug; diagnosis of osteomyelitis after Study Day 8; or death caused by cSSSI. Indeterminate: Inability to determine an outcome

  8-15 days after the end of treatment

• Clinical Cure Rate of Ceftaroline Compared With That of Vancomycin Plus Aztreonam Treatment at TOC in the Clinically Evaluable (CE) Population

  8-15 days after last dose of study drug

Secondary Outcomes (6)

• Microbiological Success Rate at the TOC Visit

  8-15 days after last dose of study drug

• Clinical Response at the End of Therapy (EOT) Visit

  Last day of study drug administration

• Clinical and Microbiological Response by Pathogen at the TOC Visit

  8-15 days after last dose of study drug

• Clinical Relapse at the Late Follow Up (LFU) Visit

  21 to 35 days after the last dose of study drug

• Microbiological Reinfection or Recurrence at the LFU Visit

  21 to 35 days after the last dose of study drug

Study Arms (2)

Ceftaroline for Injection

EXPERIMENTAL

Drug: Ceftaroline

IV Vancomycin and IV Aztreonam

ACTIVE COMPARATOR

Drug: IV Vancomycin plus IV Aztreonam

Interventions

IV Vancomycin plus IV Aztreonam DRUG

vancomycin at 1 g parenteral infused over 60 minutes followed by aztreonam 1 g infused over 60 minutes, every 12 hours, for 5 to 14 days.

Also known as: Active Comparator

IV Vancomycin and IV Aztreonam

Ceftaroline DRUG

600 mg parenteral infused over 60 minutes, every 12 hours for 5 to 14 days

Also known as: Experimental

Ceftaroline for Injection

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Skin and skin structure infection (SSSI) that involves deeper soft tissue or requires significant surgical intervention, or cellulitis or abscess on lower extremity which occurs in subjects with diabetes mellitus or well-documented peripheral vascular disease.

You may not qualify if:

• Prior treatment of current cSSSI with an antimicrobial.
• Failure of vancomycin or aztreonam as therapy for the current cSSSI, or prior isolation of an organism with in vitro resistance to vancomycin or aztreonam.

Sponsors & Collaborators

• Forest Laboratories: lead

Study Sites (52)

Investigational Site

Dothan, Alabama, 36301, United States

Location

Investigational Site

Long Beach, California, 90813, United States

Location

Investigational Site

Los Angeles, California, 90015, United States

Location

Investigational Site

Sacramento, California, 95817, United States

Location

Investigational Site

Sacramento, California, 95819, United States

Location

Investigational Site

San Diego, California, 92114, United States

Location

Investigational Site

San Francisco, California, 94110, United States

Location

Investigational Site

Torrance, California, 90509, United States

Location

Investigational Site

Savannah, Georgia, 31405, United States

Location

Investigational Site

Naperville, Illinois, 60540, United States

Location

Investigational Site

Indianapolis, Indiana, 46280, United States

Location

Investigational Site

Shreveport, Louisiana, 71103, United States

Location

Investigational Site

Columbus, Ohio, 43215, United States

Location

Investigational Site

Landsdale, Pennsylvania, 19446, United States

Location

Investigational Site

Tacoma, Washington, 98405, United States

Location

Investigational Site

Buenos Aires, 1240 C1180AAX, Argentina

Location

Investigational Site

Buenos Aires, 164, Argentina

Location

Investigational Site

Buenos Aires, Argentina

Location

Invetigational Site

Buenos Aires, Argentina

Location

Investigational Site

Córdoba, Argentina

Location

Invetigational Site

Córdoba, Argentina

Location

Investigational Site

Entre Ríos, Argentina

Location

Investigational Site

Santa Fe, Argentina

Location

Investigational Site

Curiuba-Parans, 1089, Brazil

Location

Investigational Site

São Paulo, 04039-020, Brazil

Location

Investigational Site

Santiago, Chile

Location

Investigational Site

Viña del Mar, Chile

Location

Investigational Site

Berlin, D-10249, Germany

Location

Investigational Site

Bochum, 44791, Germany

Location

Investigational Site

Hanau, Germany

Location

Investigational Site

Plauen, 08529, Germany

Location

Investigational Site

Quedlinburg, 06484, Germany

Location

Investigational Site

Chihuahua City, 31238, Mexico

Location

Invetigational Site

Lima, 29, Peru

Location

Investigational Site

Bytom, 41-902, Poland

Location

Investigational Site

Krakow, 31-913, Poland

Location

Investigational Site

Lublin, 20-081, Poland

Location

Investigational Site

Sosnowiec, 41-200, Poland

Location

Investigational Site

Todz, 91-425, Poland

Location

Investigational Site

Bucharest, 010816, Romania

Location

Investigational Site

Bucharest, 041915, Romania

Location

Investigational Site

Timișoara, 300736, Romania

Location

Investigational Site

Moscow, 105229, Russia

Location

Investigational Site

Moscow, 111539, Russia

Location

Investigational Site

Moscow, 129327, Russia

Location

Investigational Site

Saint Petersburg, 192242, Russia

Location

Investigational Site

Saint Petersburg, 194354, Russia

Location

Investigational Site

Saint Petersburg, 196247, Russia

Location

Investigational Site

Smolensk, 214019, Russia

Location

Investigational Site

Dnipropetrovsk, 49600, Ukraine

Location

Investigational Site

Ivano-Frankivsk, 76008, Ukraine

Location

Investigational Site

Lviv, 79659, Ukraine

Location

Related Publications (7)

• Dryden M, Kantecki M, Yan JL, Stone GG, Leister-Tebbe H, Wilcox M. Treatment outcomes of secondary bacteraemia in patients treated with ceftaroline fosamil: pooled results from six phase III clinical trials. J Glob Antimicrob Resist. 2022 Mar;28:108-114. doi: 10.1016/j.jgar.2021.10.027. Epub 2021 Dec 16.

  PMID: 34922058 DERIVED

• Wilcox M, Yan JL, Gonzalez PL, Dryden M, Stone GG, Kantecki M. Impact of Underlying Comorbidities on Outcomes of Patients Treated with Ceftaroline Fosamil for Complicated Skin and Soft Tissue Infections: Pooled Results from Three Phase III Randomized Clinical Trials. Infect Dis Ther. 2022 Feb;11(1):217-230. doi: 10.1007/s40121-021-00557-w. Epub 2021 Nov 6.

  PMID: 34741280 DERIVED

• Corey GR, Wilcox MH, Gonzalez J, Jandourek A, Wilson DJ, Friedland HD, Das S, Iaconis J, Dryden M. Ceftaroline fosamil therapy in patients with acute bacterial skin and skin-structure infections with systemic inflammatory signs: A retrospective dose comparison across three pivotal trials. Int J Antimicrob Agents. 2019 Jun;53(6):830-837. doi: 10.1016/j.ijantimicag.2019.01.016. Epub 2019 Feb 1.

  PMID: 30716446 DERIVED

• Cheng K, Pypstra R, Yan JL, Hammond J. Summary of the safety and tolerability of two treatment regimens of ceftaroline fosamil: 600 mg every 8 h versus 600 mg every 12 h. J Antimicrob Chemother. 2019 Apr 1;74(4):1086-1091. doi: 10.1093/jac/dky519.

  PMID: 30597021 DERIVED

• Corrado ML. Integrated safety summary of CANVAS 1 and 2 trials: Phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010 Nov;65 Suppl 4:iv67-iv71. doi: 10.1093/jac/dkq256.

  PMID: 21115456 DERIVED

• Corey GR, Wilcox MH, Talbot GH, Thye D, Friedland D, Baculik T; CANVAS 1 investigators. CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010 Nov;65 Suppl 4:iv41-51. doi: 10.1093/jac/dkq254.

  PMID: 21115454 DERIVED

• Corey GR, Wilcox M, Talbot GH, Friedland HD, Baculik T, Witherell GW, Critchley I, Das AF, Thye D. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis. 2010 Sep 15;51(6):641-50. doi: 10.1086/655827.

  PMID: 20695801 DERIVED

MeSH Terms

Conditions

Bacterial Infections; Abscess; Skin Diseases, Bacterial; Cellulitis; Staphylococcal Skin Infections; Staphylococcal Infections; Surgical Wound Infection

Interventions

Vancomycin; Aztreonam; Ceftaroline

Condition Hierarchy (Ancestors)

Bacterial Infections and Mycoses; Infections; Suppuration; Inflammation; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Skin Diseases, Infectious; Skin Diseases; Skin and Connective Tissue Diseases; Connective Tissue Diseases; Gram-Positive Bacterial Infections; Wound Infection; Postoperative Complications

Intervention Hierarchy (Ancestors)

Glycopeptides; Glycoconjugates; Carbohydrates; Peptides; Amino Acids, Peptides, and Proteins; Monobactams; beta-Lactams; Lactams; Amides; Organic Chemicals; Sulfur Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Cephalosporins; Thiazines

Results Point of Contact

• Title: Vice President, Clinical Sciences
• Organization: Cerexa

clinicaltrials@cerexa.com

(510) 285-9200

Study Officials

• Ralph Corey, MD

  Duke University

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: January 16, 2007
• First Posted: January 18, 2007
• Study Start: February 1, 2007
• Primary Completion: November 1, 2007
• Study Completion: November 1, 2007
• Last Updated: March 14, 2017
• Results First Posted: November 8, 2010

Record last verified: 2017-02

Locations

RO (3); US (15); ME (1); PE (1); CL (2); DE (5); RU (7); AR (8); PL (5); BR (2); UA (3)